相似文献
1
Gliomas arising in the setting of Li-Fraumeni syndrome stratify into two molecular subgroups with divergent clinicopathologic features.
Acta Neuropathol. 2020 May;139(5):953-957. doi: 10.1007/s00401-020-02144-8. Epub 2020 Mar 10.
2
Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome.
Hum Mutat. 2014 Jun;35(6):654-62. doi: 10.1002/humu.22559.
3
Pediatric high-grade glioma MYCN is frequently associated with Li-Fraumeni syndrome.
Acta Neuropathol Commun. 2023 Jan 6;11(1):3. doi: 10.1186/s40478-022-01490-w.
4
Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
Mol Carcinog. 2013 Oct;52(10):770-6. doi: 10.1002/mc.21912. Epub 2012 Apr 11.
5
Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Li-Fraumeni syndrome.
Leukemia. 2021 May;35(5):1475-1479. doi: 10.1038/s41375-021-01163-y. Epub 2021 Feb 12.
6
p53+/mdm2- atypical lipomatous tumor/well-differentiated liposarcoma in young children: an early expression of Li-Fraumeni syndrome.
Pediatr Dev Pathol. 2010 May-Jun;13(3):218-24. doi: 10.2350/09-08-0694-OA.1.
7
Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.
Lancet Oncol. 2016 Sep;17(9):1295-305. doi: 10.1016/S1470-2045(16)30249-2. Epub 2016 Aug 5.
8
Nodular Lymphocyte-predominant Hodgkin Lymphoma in a 15-Year-Old Boy With Li-Fraumeni Syndrome Having a Germline TP53 D49H Mutation.
J Pediatr Hematol Oncol. 2018 Apr;40(3):e195-e197. doi: 10.1097/MPH.0000000000000948.
9
A novel germ-line mutation in the noncoding region of the p53 gene in a Li-Fraumeni family.
Cancer Genet Cytogenet. 1998 May;103(1):1-6. doi: 10.1016/s0165-4608(97)00258-6.
10
The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
Cancer Lett. 2007 Jan 8;245(1-2):96-102. doi: 10.1016/j.canlet.2005.12.039. Epub 2006 Feb 21.
引用本文的文献
1
National and subnational burden of brain and central nervous system cancers in China and global from 1990 to 2021: results from the global burden of disease study 2021.
Arch Public Health. 2025 Jul 28;83(1):195. doi: 10.1186/s13690-025-01683-4.
2
A systematic review of high-grade glioma associated with Li-Fraumeni syndrome.
Neurosurg Rev. 2025 Mar 10;48(1):290. doi: 10.1007/s10143-025-03437-w.
3
Longitudinal profiling of IDH-mutant astrocytomas reveals acquired RAS-MAPK pathway mutations associated with inferior survival.
Neurooncol Adv. 2025 Jan 29;7(1):vdaf024. doi: 10.1093/noajnl/vdaf024. eCollection 2025 Jan-Dec.
4
Pediatric high-grade gliomas with concomitant RB1 and SETD2 alterations and Li-Fraumeni syndrome.
Acta Neuropathol Commun. 2025 Jan 16;13(1):8. doi: 10.1186/s40478-024-01885-x.
5
Dual PTCH2 mutation [Ser391*, Leu104Pro]: unveiling a potential new genetic susceptibility factor for glioma development.
Invest New Drugs. 2025 Feb;43(1):126-134. doi: 10.1007/s10637-024-01491-7. Epub 2025 Jan 13.
6
Current insights and future directions of Li-Fraumeni syndrome.
Discov Oncol. 2024 Oct 15;15(1):561. doi: 10.1007/s12672-024-01435-w.
7
Revolutionizing Glioblastoma Treatment: A Comprehensive Overview of Modern Therapeutic Approaches.
Int J Mol Sci. 2024 May 26;25(11):5774. doi: 10.3390/ijms25115774.
8
Glioma.
Nat Rev Dis Primers. 2024 May 9;10(1):33. doi: 10.1038/s41572-024-00516-y.
9
Pediatric-type high-grade gliomas with PDGFRA amplification in adult patients with Li-Fraumeni syndrome: clinical and molecular characterization of three cases.
Acta Neuropathol Commun. 2024 Apr 11;12(1):57. doi: 10.1186/s40478-024-01762-7.
10
Case report: Turcot syndrome type 2 in a developing country within the Caribbean.
Front Oncol. 2024 Mar 14;14:1331271. doi: 10.3389/fonc.2024.1331271. eCollection 2024.
本文引用的文献
1
An update on the central nervous system manifestations of Li-Fraumeni syndrome.
Acta Neuropathol. 2020 Apr;139(4):669-687. doi: 10.1007/s00401-019-02055-3. Epub 2019 Aug 30.
2
The molecular landscape of glioma in patients with Neurofibromatosis 1.
Nat Med. 2019 Jan;25(1):176-187. doi: 10.1038/s41591-018-0263-8. Epub 2018 Dec 10.
3
Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts.
Acta Neuropathol Commun. 2018 Sep 19;6(1):95. doi: 10.1186/s40478-018-0598-x.
4
The genetic landscape of gliomas arising after therapeutic radiation.
Acta Neuropathol. 2019 Jan;137(1):139-150. doi: 10.1007/s00401-018-1906-z. Epub 2018 Sep 8.
5
The genetic landscape of ganglioglioma.
Acta Neuropathol Commun. 2018 Jun 7;6(1):47. doi: 10.1186/s40478-018-0551-z.
6
Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort.
Lancet Oncol. 2018 Jun;19(6):785-798. doi: 10.1016/S1470-2045(18)30242-0. Epub 2018 May 9.
7
Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas.
Neuro Oncol. 2018 Apr 9;20(5):632-641. doi: 10.1093/neuonc/nox205.
8
Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome.
Clin Cancer Res. 2017 Jun 1;23(11):e38-e45. doi: 10.1158/1078-0432.CCR-17-0408.
9
Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.
Neuro Oncol. 2017 May 1;19(5):699-709. doi: 10.1093/neuonc/now254.
10
IDH1 mutation can be present in diffuse astrocytomas and giant cell glioblastomas of young children under 10 years of age.
Acta Neuropathol. 2016 Jul;132(1):153-5. doi: 10.1007/s00401-016-1579-4. Epub 2016 May 9.
Zotero 插件